Emperra Appoints Christian Krey as New CEO To Market ESYSTA® Telediabetology System
|| Print ||
|Tuesday, 11 February 2014 11:00 (UTC + 1)|
Potsdam, Germany, February 11, 2014 / B3C newswire / - EMPERRA® GmbH E-Health Technologies, specializing in e-health technologies and telediabetology, today announced the appointment of Dr. Christian Krey as Managing Director and CEO. Dr. Krey has many years of experience in the field of diabetes mellitus and was previously employed as Business Unit Manager at a Johnson & Johnson subsidiary. Prior to that, Dr. Krey held various positions in the field of diabetes at Lilly, Berlin Chemie and A. Menarini Diagnostics. In the future, Dr. Mertens, who has held the position of Managing Director and CEO for the past three years, will be assuming the role of VP Business Development. Dr. Schildt continues to be the responsible Managing Director for the fields of Medicine and Technology.
For the first time, ESYSTA® enables all data such as insulin dose, blood glucose readings and carbohydrate units are completely recorded. Via cell phone and with the assistance of a Web-based assessment platform, all relevant data are always available on computers, tablets and smart phones (Android®/iOS®) not only to patients/family members but also to physicians in private practice and clinics. ESYSTA® significantly improves diagnostics, therapy, patient guidance, patient compliance, self-empowerment and quality of life. The ESYSTA® product system additionally leads to a significant cost reduction for statutory health funds and reimbursers for the highly-prevalent, cost-intensive chronic illness, "diabetes mellitus".
With the patented ESYSTA® pen, for the first time worldwide, there is now an insulin pen that uses all insulins of major insulin suppliers and can thus be used for all patients without having to change the insulin therapy. The ESYSTA® insulin pen ensures that all insulin doses administered by patients are recorded, transmitted via wireless and documented in the ESYSTA® portal.
Dr. Christian Krey, Managing Director and CEO of EMPERRA® GmbH explains: “I am very happy to be at Emperra and to utilise my many years of experience in the field of diabetes, in order to position in the market and further develop the ESYSTA® system. This system is unique and will help improve the care for persons with diabetes. For the first time, it enables all stakeholders to be involved."
Dr. Christian Krey
Dr. Klaus Stöckemann